Add Formweb to your mobile device
Approved Formulary
Search results for:
donepezil
donepezil
Brand names: Aricept
| Form | Strength |
|---|---|
| TABLET, DISINTEGRATING, ORAL | 10 mg |
| TABLET, ORAL | 5 mg; 10 mg |
Display Parasympathomimetic (Cholinergic) Agents Class:
120400
Medication comments:
| Per policy, orders for these non-formulary agents will be changed to formulary equivalents. | |
|---|---|
| Non-Formulary Agent | Formulary Equivalent |
| donepezil (Aricept) 23 mg | donepezil (Aricept) 20 mg |
| 2023 American Geriatrics Society Beers Criteria® for potentially inappropriate medication use in older adults. | |
|---|---|
| Medication: | donepezil (Aricept) |
| Criteria 2: Potentially inappropriate medication use in older adults due to drug–disease or drug–syndrome interactions that may exacerbate the disease or syndrome. (Table 3) | |
| Drug(s) ⇆ disease or syndrome | cholinesterase inhibitors (AChEIs) ⇄ Syncope |
| Rationale | AChEIs cause bradycardia and should be avoided in older adults whose syncope may be due to bradycardia. |
| Recommendation | Avoid |
| Quality of evidence: High, Strength of Recommendation: Strong | |
Last updated: Sep. 24, 2025